Associate Professor (OBE)
Honorary Officer of the Most Excellent Order of the British Empire (OBE), for services to Science and Public Health.
Vaccines are efficacious cost-effective healthcare measures and a global mainstay in protecting millions from infectious disease. The establishment of protective immune responses following vaccination and the formation of adaptive immune memory are crucial for ensuring long-lived immunity toward infectious disease.
At the Jenner Institute we use platform technologies to develop vaccines against emerging and re-emerging pathogens. The Lambe group is currently developing vaccines against a number of outbreak pathogens including Crimean-Congo haemorrhagic fever virus, Lassa virus, Nipah virus, Influenza, Ebolavirus and coronaviruses. A number of these vaccines have progressed through preclinical works and are being assessed in clinical trials.
We are particularly interested in delineating the immune response post vaccination and also post natural infection to define correlates of protection. As part of the Covid-19 vaccine trial as well as for many of these other vaccines the Lambe group has led on the development and validation of detailed immunological assays for the analysis in both vaccine volunteers and clinical patients.
We are currently focusing on developing a vaccine (ChAdOx1 nCoV-19) against SARS-CoV-2 progressing this vaccine through preclinical assessment and working with OVG on clinical trial testing.
COVID-19 Oxford Vaccine Trial
Ratcliff J. et al, (2021)
Fischer RJ. et al, (2021), Nat Commun, 12
Swanson PA. et al, (2021), Science translational medicine, eabj7211 - eabj7211
Feng S. et al, (2021), Nat Med
Ogbe A. et al, (2021)